Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 341-347

  Qu, Geping ^a   Liu, Changting ^a   Sun, Baojun ^a   Zhou, Changxi ^a   Zhang, Zhijian ^a   Wang, Peng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Combination therapy; Erlotinib resistance; Irreversible EGFR inhibitor; Lung cancer; MET inhibitor

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPIDIUM IODIDE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; TIVANTINIB; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ADENOCARCINOMA CELL LINE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EGFR GENE; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MET GENE; MTT ASSAY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84903170988     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3178     Document Type: Article

References (28)

1. Vincent MD, Kuruvilla MS, Leighl NB and Kamel-Reid S: Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 19: S33-S44, 2012.
2. Capelletto E and Novello S: Emerging new agents for the management of patients with non-small cell lung cancer. Drugs 72 (Suppl 1): 37-52, 2012.
3. Suda K, Mizuuchi H, Maehara Y and Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation - diversity, ductility, and destiny. Cancer Metastasis Rev 31: 807-814, 2012.
4. 2 mediated cell survival in SU11274-treated non-small-cell lung cancer A549 cells via c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 pathways. J Pharmacol Sci 119: 150-159, 2012.
5. Ayoola A, Barochia A, Belani K and Belani CP: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30: 433-446, 2012.
6. Xu L, Kikuchi E, Xu C, et al: Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 72: 3302-3311, 2012.
7. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711, 2008.
8. Takezawa K, Okamoto I, Tanizaki J, et al: Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9: 1647-1656, 2010.
9. Dulak AM, Gubish CT, Stabile LP, Henry C and Siegfried JM: HGF-independent potentiation of EGFR action by c-Met. Oncogene 30: 3625-3635, 2011.
10. Nakachi I, Naoki K, Soejima K, et al: The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res 8: 1142-1151, 2010.
11. Liu X, Newton RC and Scherle PA: Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 20: 1225-1241, 2011.
12. Nakagawa T, Takeuchi S, Yamada T, et al: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11: 2149-2157, 2012.
13. Comoglio PM, Giordano S and Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7: 504-516, 2008. (Pubitemid 351767118)
14. Brambilla E and Gazdar A: Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 33: 1485-1497, 2009.
15. Suda K, Tomizawa K, Osada H, et al: Conversion from the 'oncogene addiction' to 'drug addiction' by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer 76: 292-299, 2012.
16. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472-3475, 2002. (Pubitemid 34525335)
17. Choi YL, Soda M, Yamashita Y, et al: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739, 2010.
18. Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15: 2552-2558, 2009.
19. Guo A, Villen J, Kornhauser J, et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697, 2008. (Pubitemid 351171770)
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
21. Tang Z, Du R, Jiang S, et al: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 99: 911-922, 2008.
22. Suda K, Murakami I, Katayama T, et al: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16: 5489-5498, 2010.
23. Bonanno L, Jirillo A and Favaretto A: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr Drug Targets 12: 922-933, 2011.
24. Bowles DW, Weickhardt A and Jimeno A: Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today 49: 523-535, 2013.
25. Nelson V, Ziehr J, Agulnik M and Johnson M: Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 6: 135-143, 2013.
26. Chen X, Zhu Q, Zhu L, et al: Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer 81: 155-161, 2013.
27. Wang W, Li Q, Takeuchi S, et al: Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18: 1663-1671, 2012.
28. Koizumi H, Yamada T, Takeuchi S, et al: Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol 7: 1078-1085, 2012.